These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 25448549)

  • 1. Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies.
    Maksimenko A; Caron J; Mougin J; Desmaële D; Couvreur P
    Int J Pharm; 2015 Mar; 482(1-2):38-46. PubMed ID: 25448549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer.
    Réjiba S; Reddy LH; Bigand C; Parmentier C; Couvreur P; Hajri A
    Nanomedicine; 2011 Dec; 7(6):841-9. PubMed ID: 21419876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of an amphiphilic squalenoyl prodrug of gemcitabine with cellular membranes.
    Bildstein L; Pili B; Marsaud V; Wack S; Meneau F; Lepêtre-Mouelhi S; Desmaële D; Bourgaux C; Couvreur P; Dubernet C
    Eur J Pharm Biopharm; 2011 Nov; 79(3):612-20. PubMed ID: 21784150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types.
    Reddy LH; Dubernet C; Mouelhi SL; Marque PE; Desmaele D; Couvreur P
    J Control Release; 2007 Dec; 124(1-2):20-7. PubMed ID: 17878060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polyisoprenoyl gemcitabine conjugates self assemble as nanoparticles, useful for cancer therapy.
    Maksimenko A; Mougin J; Mura S; Sliwinski E; Lepeltier E; Bourgaux C; Lepêtre S; Zouhiri F; Desmaële D; Couvreur P
    Cancer Lett; 2013 Jul; 334(2):346-53. PubMed ID: 22935679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: an original drug delivery pathway.
    Bildstein L; Dubernet C; Marsaud V; Chacun H; Nicolas V; Gueutin C; Sarasin A; Bénech H; Lepêtre-Mouelhi S; Desmaële D; Couvreur P
    J Control Release; 2010 Oct; 147(2):163-70. PubMed ID: 20691740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Squalenoyl nanomedicine of gemcitabine is more potent after oral administration in leukemia-bearing rats: study of mechanisms.
    Reddy LH; Ferreira H; Dubernet C; Mouelhi SL; Desmaele D; Rousseau B; Couvreur P
    Anticancer Drugs; 2008 Nov; 19(10):999-1006. PubMed ID: 18827565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide-functionalized nanoparticles for selective targeting of pancreatic tumor.
    Valetti S; Maione F; Mura S; Stella B; Desmaële D; Noiray M; Vergnaud J; Vauthier C; Cattel L; Giraudo E; Couvreur P
    J Control Release; 2014 Oct; 192():29-39. PubMed ID: 24984010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetoresponsive squalenoyl gemcitabine composite nanoparticles for cancer active targeting.
    Arias JL; Reddy LH; Couvreur P
    Langmuir; 2008 Jul; 24(14):7512-9. PubMed ID: 18540685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation of intravenous injection nanoformulation of VESylated gemcitabine by co-assembly with TPGS and its anti-tumor activity in pancreatic tumor-bearing mice.
    Xu Y; Meng H; Du F; Lu W; Liu S; Huang J; Yu J
    Int J Pharm; 2015 Nov; 495(2):792-7. PubMed ID: 26410754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Squalenoyl nucleoside monophosphate nanoassemblies: new prodrug strategy for the delivery of nucleotide analogues.
    Caron J; Reddy LH; Lepêtre-Mouelhi S; Wack S; Clayette P; Rogez-Kreuz C; Yousfi R; Couvreur P; Desmaële D
    Bioorg Med Chem Lett; 2010 May; 20(9):2761-4. PubMed ID: 20363623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A unique multidrug nanomedicine made of squalenoyl-gemcitabine and alkyl-lysophospholipid edelfosine.
    Rodríguez-Nogales C; Sebastián V; Irusta S; Desmaële D; Couvreur P; Blanco-Prieto MJ
    Eur J Pharm Biopharm; 2019 Nov; 144():165-173. PubMed ID: 31546021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Freeze-drying of squalenoylated nucleoside analogue nanoparticles.
    Bildstein L; Hillaireau H; Desmaële D; Lepêtre-Mouelhi S; Dubernet C; Couvreur P
    Int J Pharm; 2009 Nov; 381(2):140-5. PubMed ID: 19782881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer efficacy of squalenoyl gemcitabine nanomedicine on 60 human tumor cell panel and on experimental tumor.
    Reddy LH; Renoir JM; Marsaud V; Lepetre-Mouelhi S; Desmaële D; Couvreur P
    Mol Pharm; 2009; 6(5):1526-35. PubMed ID: 19634915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-circulatory nanoparticles for gemcitabine delivery: Development and investigation of pharmacokinetics and in-vivo anticancer efficacy.
    Khare V; Singh A; Mahajan G; Alam N; Kour S; Gupta M; Kumar A; Singh G; Singh SK; Saxena AK; Mondhe DM; Gupta PN
    Eur J Pharm Sci; 2016 Sep; 92():183-93. PubMed ID: 27404580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-Assembled Gemcitabine Prodrug Nanoparticles Show Enhanced Efficacy against Patient-Derived Pancreatic Ductal Adenocarcinoma.
    Wu L; Zhang F; Chen X; Wan J; Wang Y; Li T; Wang H
    ACS Appl Mater Interfaces; 2020 Jan; 12(3):3327-3340. PubMed ID: 31872760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interfacial behavior of PEGylated lipids and their effect on the stability of squalenoyl-drug nanoassemblies.
    Bekkara-Aounallah F; Ambike A; Gref R; Couvreur P; Rosilio V
    Int J Pharm; 2014 Aug; 471(1-2):75-82. PubMed ID: 24811925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diels Alder-mediated release of gemcitabine from hybrid nanoparticles for enhanced pancreatic cancer therapy.
    Oluwasanmi A; Al-Shakarchi W; Manzur A; Aldebasi MH; Elsini RS; Albusair MK; Haxton KJ; Curtis ADM; Hoskins C
    J Control Release; 2017 Nov; 266():355-364. PubMed ID: 28943195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Squalenoylation favorably modifies the in vivo pharmacokinetics and biodistribution of gemcitabine in mice.
    Reddy LH; Khoury H; Paci A; Deroussent A; Ferreira H; Dubernet C; Declèves X; Besnard M; Chacun H; Lepêtre-Mouelhi S; Desmaële D; Rousseau B; Laugier C; Cintrat JC; Vassal G; Couvreur P
    Drug Metab Dispos; 2008 Aug; 36(8):1570-7. PubMed ID: 18474674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and evaluation of folate functionalized albumin nanoparticles for targeted delivery of gemcitabine.
    Dubey RD; Alam N; Saneja A; Khare V; Kumar A; Vaidh S; Mahajan G; Sharma PR; Singh SK; Mondhe DM; Gupta PN
    Int J Pharm; 2015 Aug; 492(1-2):80-91. PubMed ID: 26165611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.